Loading
TQB3616 is an experimental small-molecule drug from Chia Tai Tianqing Pharmaceutical in phase 3 trials for HR-positive / HER2-negative breast cancer, aimed at CDK4/6.
TQB3616 is a small-molecule drug developed by Chia Tai Tianqing Pharmaceutical. Its target is CDK4/6 (the sponsor names CDK4/6). The sponsor states: TQB3616 is a novel oral cyclin-dependent kinase (CDK) 4/6 inhibitor used in the treatment of various malignant solid tumours. ClinicalTrials.gov describes the intervention as: TQB3616 capsule is a Cyclin-dependent kinase 4/6 (CDK4/6) inhibitor. It is the investigational product in 4 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including phase 3 studies NCT05780567 (Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer) and NCT05365178 (To Evaluate the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated Hormone-receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer), in HR-positive / HER2-negative breast cancer. The largest, NCT05780567, plans to enrol 1946 participants with primary completion expected 2026-12. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
TQB3616 is a novel oral cyclin-dependent kinase (CDK) 4/6 inhibitor used in the treatment of various malignant solid tumours. Connects to CDK4/6.
1.TQB3616 slips into a pocket on CDK4/6.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"TQB3616" OR ABSTRACT:"TQB3616") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about TQB3616, not a curated reading list.
Shares A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer, Sino Biopharmaceutical (Chia Tai Tianqing), HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares CDK4/6, HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares Sino Biopharmaceutical (Chia Tai Tianqing) and the tag pipeline.
Shares Sino Biopharmaceutical (Chia Tai Tianqing) and the tag pipeline.
Shares Sino Biopharmaceutical (Chia Tai Tianqing) and the tag pipeline.
Shares Sino Biopharmaceutical (Chia Tai Tianqing) and the tag pipeline.
Shares Sino Biopharmaceutical (Chia Tai Tianqing) and the tag pipeline.
Shares Sino Biopharmaceutical (Chia Tai Tianqing) and the tag pipeline.